<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779545</url>
  </required_header>
  <id_info>
    <org_study_id>P03748</org_study_id>
    <secondary_id>JPC-03-342-20</secondary_id>
    <nct_id>NCT00779545</nct_id>
  </id_info>
  <brief_title>A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED)</brief_title>
  <official_title>Dose Finding and Dose Regimen Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind within the dose level, parallel group&#xD;
      comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to&#xD;
      examine the minimal effective dose, the recommended dose, and the dosing regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2004</start_date>
  <completion_date type="Actual">August 6, 2004</completion_date>
  <primary_completion_date type="Actual">August 6, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 4 nasal symptom score (sneezing attack, rhinorrhea, nasal congestion, and nasal itching) from baseline at Week 2</measure>
    <time_frame>After 2 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in each nasal symptom (sneezing attack, rhinorrhea, nasal congestion, and nasal itching)</measure>
    <time_frame>After 1 and 2 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall improvement</measure>
    <time_frame>After 1 and 2 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL score</measure>
    <time_frame>At initial day of treatment and after 2 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From initial day of treatment until 7-10 days after treatment is stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory tests</measure>
    <time_frame>From initial day of treatment until treatment is stopped.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate nasal spray 100 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate nasal spray 200 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate nasal spray 400 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate nasal spray 100 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate nasal spray 200 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.</description>
    <arm_group_label>Mometasone furoate nasal spray 100 mcg QD</arm_group_label>
    <arm_group_label>Mometasone furoate nasal spray 200 mcg QD</arm_group_label>
    <arm_group_label>Mometasone furoate nasal spray 400 mcg QD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.</description>
    <arm_group_label>Mometasone furoate nasal spray 100 mcg QD</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.</description>
    <arm_group_label>Mometasone furoate nasal spray 200 mcg QD</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.</description>
    <arm_group_label>Mometasone furoate nasal spray 400 mcg QD</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.</description>
    <arm_group_label>Mometasone furoate nasal spray 100 mcg BID</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.</description>
    <arm_group_label>Mometasone furoate nasal spray 200 mcg BID</arm_group_label>
    <other_name>Nasonex</other_name>
    <other_name>SCH 32088</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of mongoloid race residing in Japan who satisfy all of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Patients having symptoms of allergic rhinitis of moderate or severe degree,&#xD;
                  according to the classification of severity in the guidelines for the treatment&#xD;
                  of nasal allergy (partial revision) as well as a score of at least 4 in the score&#xD;
                  of 4 nasal symptoms, at the time of obtaining the informed consent during the&#xD;
                  pretreatment observation period.&#xD;
&#xD;
               -  Patients in whom the skin or specific IgE test is positive and the cytological&#xD;
                  examination for eosinophils in nasal discharge or nasal challenge test is&#xD;
                  positive.&#xD;
&#xD;
               -  Out-patients aged 16 years or over at the time of obtaining the informed consent.&#xD;
&#xD;
               -  Male or female.&#xD;
&#xD;
               -  Patients from whom the informed consent can be obtained in writing (or the&#xD;
                  informed consent can be obtained from the patient's legally acceptable&#xD;
                  representative, if under 20 years).&#xD;
&#xD;
               -  Patients who can daily complete the nasal allergy diary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet any of the following exclusion criteria are not included in the&#xD;
             present study:&#xD;
&#xD;
               -  Patients with a complication of tuberculous disease or lower respiratory tract&#xD;
                  infection, or patients with a complication of acute upper respiratory tract&#xD;
                  inflammation or acute laryngopharyngitis which the (sub) investigator considers&#xD;
                  necessary to treat at the time of enrollment in the treatment.&#xD;
&#xD;
               -  Patients with a complication of infection or systemic mycosis for which no&#xD;
                  effective antibiotics are available.&#xD;
&#xD;
               -  Patients with unhealed nasal septum ulcer, nasal surgery, or nasal trauma.&#xD;
&#xD;
               -  Patients with hypersensitivity to steroids and mometasone furoate.&#xD;
&#xD;
               -  Patients who are pregnant, nursing, or possibly pregnant, or who desire to become&#xD;
                  pregnant during the study period.&#xD;
&#xD;
               -  Patients with severe hepatic, renal, or cardiac disorder, blood disease,&#xD;
                  diabetes, hypertension, or other serious complication, suffering from problems&#xD;
                  with systemic condition.&#xD;
&#xD;
               -  Patients in whom pollen is an overlapping allergen and the study is planned to be&#xD;
                  implemented in the pollen release season.&#xD;
&#xD;
               -  Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis.&#xD;
&#xD;
               -  Patients with a complication of nose disease which may interfere with efficacy&#xD;
                  evaluation of the investigational product.&#xD;
&#xD;
               -  Patients who were complicated by acute upper respiratory tract inflammation&#xD;
                  during the 7-day observation period prior to enrollment which may affect the&#xD;
                  nasal symptoms.&#xD;
&#xD;
               -  Patients who have previously received mometasone furoate nasal spray.&#xD;
&#xD;
               -  Patients who have participated in clinical trial of other investigational&#xD;
                  product(s) within 4 months before obtaining the informed consent or are&#xD;
                  participating at present.&#xD;
&#xD;
               -  Patients in whom prior medication effective against allergic rhinitis was&#xD;
                  withdrawn not long enough before initiation of treatment with the investigational&#xD;
                  product or the preceding medication cannot be withdrawn.&#xD;
&#xD;
               -  Patients who are being treated with specific desensitization therapy or&#xD;
                  nonspecific allassotherapy or in whom such the therapy was withdrawn within 3&#xD;
                  months before obtaining the informed consent (except for patients receiving the&#xD;
                  maintenance therapy at present in whom the therapy began more than 6 months&#xD;
                  before obtaining the informed consent).&#xD;
&#xD;
               -  Other patients whom the (sub) investigator judged to be inappropriate for&#xD;
                  participation in the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

